CLINICAL TRIALS PROFILE FOR SAQUINAVIR MESYLATE

All Clinical Trials for saquinavir mesylate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001040 ↗	Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC	Completed	Hoffmann-La Roche	Phase 2	1969-12-31	PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.
NCT00002111 ↗	A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.	Completed	Stanford University	Phase 1	1969-12-31	To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
NCT00002333 ↗	A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine	Completed	Hoffmann-La Roche	Phase 2	1969-12-31	To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
NCT00002334 ↗	A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment	Completed	Hoffmann-La Roche	Phase 3	1969-12-31	To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
NCT00003008 ↗	Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma	Completed	AIDS Associated Malignancies Clinical Trials Consortium	Phase 2	1997-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.
NCT00003008 ↗	Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.

Clinical Trial Conditions for saquinavir mesylate

Condition Name

Condition Name for saquinavir mesylate
Intervention	Trials
HIV Infections	6
Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID	1
Sarcoma	1

Condition MeSH

Condition MeSH for saquinavir mesylate
Intervention	Trials
HIV Infections	6
Acquired Immunodeficiency Syndrome	2
Infections	1
Infection	1

Clinical Trial Locations for saquinavir mesylate

Trials by Country

Trials by Country for saquinavir mesylate
Location	Trials
United States	52
Canada	4
Puerto Rico	3

Trials by US State

Trials by US State for saquinavir mesylate
Location	Trials
California	5
Massachusetts	4
Ohio	4
New York	4
Washington	3

Clinical Trial Progress for saquinavir mesylate

Clinical Trial Phase

Clinical Trial Phase for saquinavir mesylate
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for saquinavir mesylate
Clinical Trial Phase	Trials
Completed	7
Withdrawn	1

Clinical Trial Sponsors for saquinavir mesylate

Sponsor Name

Sponsor Name for saquinavir mesylate
Sponsor	Trials
Hoffmann-La Roche	3
National Cancer Institute (NCI)	1
Eastern Cooperative Oncology Group	1

Sponsor Type

Sponsor Type for saquinavir mesylate
Sponsor	Trials
Other	5
Industry	4
NIH	2